| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c63c0c7e4d596e3495d2c733d889e131
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_baee372c55802742f9582e25c15ff11a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0d8ff672bb39f6fce7692804633e2609
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e6b51d334ca5e6370a7e99c924fc84ec
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_288e67a756612411b23a93f77b471627 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-453
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-445
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-445 |
| filingDate |
2018-03-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_da6aa650fa389c820c2573057b145844
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_308ca46a0e72ebd7e40a45da84ed5a54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_63dc05abb6b7ffb0c0d9b291d2d2c8fc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_877edeb891729f3c077894d109882e54 |
| publicationDate |
2018-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2018170447-A1 |
| titleOfInvention |
Combination therapies for the treatment of breast cancer |
| abstract |
Provided herein is a combination therapy useful for the treatment breast cancer. The combination comprises an ER-alpha inhibitor and a CDK 4/6 inhibitor. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3544967-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11357779-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022098953-A1 |
| priorityDate |
2017-03-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |